13hpotre(gamma)

Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the alpha subunit of the interleukin-4 receptor, thereby inhibiting IL-4 and IL-13 signaling. As a systemic immunomodulator, it has demonstrated efficacy in improving atopic dermatitis.

Lebrikizumab is a humanised monoclonal antibody that targets and inhibits interleukin 13 (IL-13), thereby suppressing Th2 inflammation. It is mainly used in the study of asthma and atopic dermatitis.

Tralokinumab is a fully human IgG4 monoclonal antibody with a high affinity for IL-13 alone. Tralokinumab's potential anti-inflammatory activity prevents IL-13 receptor interaction and subsequent downstream signaling and can be used to study atopic dermatitis (AD).

Rolinsatamab is a fully humanized selective monoclonal antibody that is a potent dual inhibitor of IL-4 and IL-13. Rolinsatamab chimeric antigen receptor sequence T cells. Rolinsatamab can be used to prevent and treat immune diseases.

Abrezekimab (VR 942) is composed of CDP7766, leucine, and trehalose. Abrezekimab is a humanized antibody that targets human IL-13. Abrezekimab inhibits binding to IL-13Rα1 subunit. Abrezekimab can be used to study biological disorders associated with asthma and lung disease.

Anrukinzumab (IMA-638) is a humanized monoclonal antibody that specifically targets and neutralizes interleukin-13 (IL-13). Anrukinzumab has demonstrated significant anti-inflammatory effects in validated non-human primate models of disease, supporting its ongoing research for the treatment of ulcerative colitis (UC) and asthma.

Cendakimab (RPC4046) is a humanized monoclonal antibody targeting IL-13. It selectively targets the IL-13 receptor (IL13R-α1 and IL13R-α2), used in research on atopic dermatitis.

Manfidokimab (AK120) is a human monoclonal antibody of the IgG4 subclass that specifically targets the interleukin-4 receptor alpha subunit (IL-4Rα). by binding to this shared subunit, Manfidokimab simultaneously blocks the downstream signaling pathways of both interleukin-4 (IL-4) and interleukin-13 (IL-13), and Manfidokimab can be used in studies about moderate to severe atopic dermatitis.

Dectrekumab (QAX576) is a humanized monoclonal antibody targeting IL-13 that reduces the number of eosinophils in the epithelium of patients with eosinophilic esophagitis (EoE), ameliorates transcriptional dysregulation associated with esophageal disease, and is indicated for use in the study of immune system disorders.

Eblasakimab (ASLAN004) is a humanized monoclonal antibody targeting the IL-13 receptor alpha. By blocking IL-4 and IL-13 signaling through type 2 receptor inhibition, it can be used for studying atopic dermatitis.

Romilkimab (SAR156597) is a chimeric humanized immunoglobulin (Ig) antibody specifically designed to target interleukins 4 and 13 (IL-4 and IL-13) [1].

Rademikibart (CBP-201) is a humanised monoclonal antibody targeting IL-4Rα (KD = 20.7 pM) that does not interact with IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signalling pathways, TF-1 cell proliferation, and TARC production in PBMCs, making it useful for studying Th2-type inflammatory diseases.

Lunsekimig (SAR443765) is an IL-13 TSLP bis-antibody that links a nano-antibody targeting IL-13 and a variable region of the heavy chain (VHH) targeting TSLP for use in asthma research.

CNTO 607 (Anti-IL-13 Antibody) is a humanized antibody targeting IL-13, used in inflammation research.

MEDI-7836 is a humanized monoclonal antibody inhibitor that targets the interleukin-13 (interleukin-13 receptor) receptor. It shows potential for research into diseases associated with inflammation.

Riltovetbart is a monoclonal antibody against IL-13, the isotype control is IgG2 κ, and its origin is canine.

Tilrekimig is a monoclonal antibody that targets human interleukin 4 (IL-4), interleukin 13 (IL-13), and TSLP (thymic stromal lymphopoietin). It shows potential for research applications in allergic and inflammatory conditions, such as asthma and atopic dermatitis.

Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). It shows potential for use in immune-mediated inflammatory diseases such as asthma and atopic dermatitis.

CNTO-5825 is a humanized monoclonal antibody inhibitor that targets interleukin-13 (IL-13). This compound shows potential for research in Th2-type inflammation-related diseases such as asthma and atopic dermatitis.